Delcath Systems (NASDAQ:DCTH) Releases Quarterly Earnings Results

Delcath Systems (NASDAQ:DCTH) released its earnings results on Tuesday. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.19, RTT News reports. The company had revenue of $0.54 million during the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative return on equity of 1,007.65% and a negative net margin of 2,308.86%. During the same period in the prior year, the company posted ($0.86) earnings per share.

Delcath Systems Price Performance

Shares of DCTH opened at $5.09 on Thursday. The company has a quick ratio of 3.11, a current ratio of 3.30 and a debt-to-equity ratio of 0.08. The firm’s 50 day simple moving average is $4.34 and its 200 day simple moving average is $3.84. Delcath Systems has a 1-year low of $2.25 and a 1-year high of $7.99.

Insider Activity

In other news, Director Gil Aharon bought 26,882 shares of the company’s stock in a transaction dated Tuesday, March 19th. The stock was bought at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the acquisition, the director now owns 1,069,710 shares in the company, valued at approximately $3,979,321.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 21.10% of the company’s stock.

Institutional Trading of Delcath Systems

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Delcath Systems by 19.7% in the fourth quarter. Vanguard Group Inc. now owns 522,008 shares of the company’s stock worth $2,172,000 after buying an additional 85,948 shares during the last quarter. Geode Capital Management LLC increased its position in Delcath Systems by 85.8% during the second quarter. Geode Capital Management LLC now owns 116,536 shares of the company’s stock valued at $679,000 after acquiring an additional 53,803 shares during the last quarter. BlackRock Inc. raised its position in Delcath Systems by 183.7% in the 2nd quarter. BlackRock Inc. now owns 47,180 shares of the company’s stock worth $275,000 after purchasing an additional 30,548 shares during the period. Northern Trust Corp grew its stake in shares of Delcath Systems by 82.7% during the fourth quarter. Northern Trust Corp now owns 60,667 shares of the company’s stock valued at $252,000 after buying an additional 27,458 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Delcath Systems during the second quarter worth $107,000. Institutional investors own 61.12% of the company’s stock.

Wall Street Analysts Forecast Growth

DCTH has been the subject of several research analyst reports. StockNews.com raised Delcath Systems to a “sell” rating in a research report on Wednesday. HC Wainwright lifted their price target on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.